One big drug is dramatically expanding the ambitions of family-owned Purdue. Now the mid-sized firm is aggressively pursuing in-licensing opportunities and building its own research capacity. Its size and private status allow it to craft flexible terms for a broad range of drugs, without worrying about Wall St. But can this inward focused company adapt to the more public requirement of its aggressive growth plans?